Expression and characterization of a single-chain polypeptide analogue of the human immunodeficiency virus type 1 gp120-CD4 receptor complex.
about
Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1Conformational Masking and Receptor-Dependent Unmasking of Highly Conserved Env Epitopes Recognized by Non-Neutralizing Antibodies That Mediate Potent ADCC against HIV-1Antigenic properties of the human immunodeficiency virus envelope glycoprotein gp120 on virions bound to target cellsAiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidatesStructural Definition of an Antibody-Dependent Cellular Cytotoxicity Response Implicated in Reduced Risk for HIV-1 InfectionDiverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 bindingHuman immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodiesSurvivors Remorse: antibody-mediated protection against HIV-1.DNA vaccines against human immunodeficiency virus type 1.Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes.N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion.Human domain antibodies to conserved sterically restricted regions on gp120 as exceptionally potent cross-reactive HIV-1 neutralizers.Discordant memory B cell and circulating anti-Env antibody responses in HIV-1 infection.Bifunctional fusion proteins of the human engineered antibody domain m36 with human soluble CD4 are potent inhibitors of diverse HIV-1 isolates.Characterization of gp120 and its single-chain derivatives, gp120-CD4D12 and gp120-M9: implications for targeting the CD4i epitope in human immunodeficiency virus vaccine design.The C108g epitope in the V2 domain of gp120 functions as a potent neutralization target when introduced into envelope proteins derived from human immunodeficiency virus type 1 primary isolates.Cross-Reactive Human IgM-Derived Monoclonal Antibodies that Bind to HIV-1 Envelope GlycoproteinsBroad-spectrum inhibition of HIV-1 by a monoclonal antibody directed against a gp120-induced epitope of CD4.Characterization of germline antibody libraries from human umbilical cord blood and selection of monoclonal antibodies to viral envelope glycoproteins: Implications for mechanisms of immune evasion and design of vaccine immunogensCrosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaquesAIDS vaccination studies using an ex vivo feline immunodeficiency virus model: failure to protect and possible enhancement of challenge infection by four cell-based vaccines prepared with autologous lymphoblastsAntibody persistence and T-cell balance: two key factors confronting HIV vaccine development.Human retroviruses after 20 years: a perspective from the past and prospects for their future control.Effects of the deletion of early region 4 (E4) open reading frame 1 (orf1), orf1-2, orf1-3 and orf1-4 on virus-host cell interaction, transgene expression, and immunogenicity of replicating adenovirus HIV vaccine vectors.HIV-1 CD4-induced (CD4i) gp120 epitope vaccines promote B and T-cell responses that contribute to reduced viral loads in rhesus macaquesAllosteric induction of the CD4-bound conformation of HIV-1 Gp120.Stabilization of HIV-1 envelope in the CD4-bound conformation through specific cross-linking of a CD4 mimeticBalance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection.Cocrystal Structures of Antibody N60-i3 and Antibody JR4 in Complex with gp120 Define More Cluster A Epitopes Involved in Effective Antibody-Dependent Effector Function against HIV-1Signature biochemical properties of broadly cross-reactive HIV-1 neutralizing antibodies in human plasma.Soluble monomeric IgG1 Fc.Beyond Oncolytics: E1B55K-Deleted Adenovirus as a Vaccine Delivery Vector.Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit immunogens.Broad HIV-1 neutralizing antibody response induced by heterologous gp140/gp145 DNA prime-vaccinia boost immunization.Fusion proteins of HIV-1 envelope glycoprotein gp120 with CD4-induced antibodies showed enhanced binding to CD4 and CD4 binding site antibodies.λ Light Chain Bias Associated With Enhanced Binding and Function of Anti-HIV Env Glycoprotein Antibodies.Antigenic conservation and immunogenicity of the HIV coreceptor binding siteImpact of IgA constant domain on HIV-1 neutralizing function of monoclonal antibody F425A1g8.Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.Full Length Single Chain Fc Protein (FLSC IgG1) as a Potent Antiviral Therapy Candidate: Implications for In Vivo Studies.
P2860
Q24645530-A95D4AF7-1E63-48CB-872E-7EE1F9D5AFE9Q26782237-5EC64469-7735-4CBE-91D2-7A5DE064CA45Q27320687-BA294814-C006-4690-ACD2-7541211070C8Q27489000-BC5F8254-D844-4E2F-97D8-811BFEFDA61BQ27640572-5481CEC1-B429-478D-97B7-741A27752CE2Q27675486-23DEE6C5-84B5-47C2-80B0-459D50816629Q29619015-55A04295-453F-4D33-A6C4-FDC00600330DQ30238730-5CDF2E13-1816-40BE-BAC1-14C7FB32DD4EQ30342130-1CAAC88C-9B6C-4DE6-813D-1131718BF332Q30706865-42904D4A-2FAB-4565-87E6-4D11F3AD9DFCQ33208281-97F62A42-21F1-4550-9765-20BCD2542150Q33380012-ECBB0ABB-153B-4119-BB21-3CBF90B9C825Q33410222-3367CAC5-785C-402B-9049-35EA17F48D3EQ33657941-1015741B-9CD6-4305-966C-A659796E9B0BQ33717477-B6AB256E-02FF-4C53-9816-B4E5A5D4CB3CQ33788792-E0FA5057-A9A6-4012-9DE6-734B77FC80E1Q33960361-EED649BC-2DE4-49B8-8091-F161D0102E9EQ33983104-C5DAE2FE-E995-41B7-A782-94D346870F11Q34121215-3BB34D10-0A35-4E2A-A156-AE4327E2A893Q34154514-9288CEF3-6F19-41BA-AB20-3D06E9258B30Q34342119-F6A6F33E-04EF-4029-8E7A-FA841D828AAAQ34480617-8B4DEED5-D08E-4546-A9A0-096C9FF70330Q34792498-D577AE2C-65D3-4026-885F-A5259BB31D29Q35021632-101A4FEB-5BF8-4089-A4A4-174A63EC5A42Q35032794-E5517E6F-6DCC-478E-8ABA-84896EA695F2Q35058860-EDDDB078-658B-4C9F-8363-7E0F2D302F4DQ35065249-684756D7-74F9-49BE-B6C9-3D0C74BCCBAFQ35156935-2D58BEB7-D901-4E9E-813E-923269779B14Q35913921-D2215615-54C8-4FBD-BAEB-91A777EC7B3BQ35943730-EFD61436-654A-4AA7-8574-3D2E1B8D3A28Q36003820-D92851EE-5E14-4B83-A9E5-EE9E03B974E5Q36071414-290B11AC-8A6E-41FA-AED6-8892EC9B49E2Q36141515-49D2D08A-BBD5-425E-8E74-04ED16177CA4Q36174694-6B20E9C2-89B8-4A1E-BC1D-AAC57438544BQ36241267-3E8F7EB3-DDD2-4372-9F30-6682F953671BQ36365309-8DF81C73-C124-47CE-81A0-5FC8398FFE49Q36403587-20D4ADC1-52A6-4166-8D42-CDDA5F5E1C4EQ36487349-A74BA97E-F3B9-409D-93B3-A7CE75A0B656Q36600380-38B0D5AC-854E-4192-B7D3-8D4C85858817Q36602029-4F9EB90B-8A93-4798-85D3-F3A087D75CE2
P2860
Expression and characterization of a single-chain polypeptide analogue of the human immunodeficiency virus type 1 gp120-CD4 receptor complex.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Expression and characterizatio ...... 1 gp120-CD4 receptor complex.
@en
Expression and characterizatio ...... 1 gp120-CD4 receptor complex.
@nl
type
label
Expression and characterizatio ...... 1 gp120-CD4 receptor complex.
@en
Expression and characterizatio ...... 1 gp120-CD4 receptor complex.
@nl
prefLabel
Expression and characterizatio ...... 1 gp120-CD4 receptor complex.
@en
Expression and characterizatio ...... 1 gp120-CD4 receptor complex.
@nl
P2093
P2860
P1433
P1476
Expression and characterizatio ...... 1 gp120-CD4 receptor complex.
@en
P2093
A L DeVico
P2860
P304
11427-11436
P356
10.1128/JVI.74.24.11427-11436.2000
P407
P577
2000-12-01T00:00:00Z